11.10 Hamburg Preliminary
Atriva Therapeutics GmbH
The ATRIVA compound is directed against a cellular factor of the host cell. In order to ensure efficient replication, the virus needs to activate this factor. ATRIVA lead compound ATR-002 prevents the virus-induced activation of the cellular factor and consequently viral replication.
Cancevir is opening new perspectives for effectively curing the cancer disease through Nucleic Acid Templated Chemistry (NATC) technology. NATC is a revolutionary, patented technology that allows the effective delivery of anticancer medications directly to cancer cells.
ISD-Immunotech is a preclinical stage com-pany developing a first-in-class therapy for the most severe Systemic lupus erythematosus (SLE) and other autoimmune diseases. The therapy works by dampening the action of an intracellular protein called STimulator of Interferon Genes (STING)
MagCath has developed and clinically tested Obtinu to help women suffering from stress incontinence. Obtinu is a single-use, very soft, silicone tube that the patient inserts and removes in the urethra daily. It has an inner valve to restore control over bladder voiding.
KidneyCure Ltd. is developing novel and proprietary, regenerative cell therapies for the treatment of advanced Chronic Kidney Disease (CKD). This therapeutic approach is expected to significantly delay the need for dialysis and kidney transplantation and to improve patients’ quality of life.
Duan Wang, Ph.D.
Senior Manager of Business Development
Jiangsu Hengrui Medicin Co., Ltd.
Kamilla Rolsted, Ph.D.
Life Science Sector Specialist
GM of European Region
Niels Christian Ganderup
Senior Investment Manager